
Luisella Bocchio-Chiavetto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7085904/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. World Journal of Biological Psychiatry, 2010, 11, 763-773.	1.3	363
2	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
3	Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Molecular Psychiatry, 2002, 7, 136-137.	4.1	223
4	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.3	197
5	Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophrenia Research, 2002, 54, 281-291.	1.1	155
6	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology, 2006, 16, 620-624.	0.3	149
7	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. Journal of Affective Disorders, 2016, 200, 250-258.	2.0	138
8	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of Affective Disorders, 2006, 91, 83-86.	2.0	137
9	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. BioMed Research International, 2013, 2013, 1-7.	0.9	137
10	Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology, 2000, 10, 119-124.	0.3	127
11	Geneââ,¬â€œEnvironment Interaction in Major Depression: Focus on Experience-Dependent Biological Systems. Frontiers in Psychiatry, 2015, 6, 68.	1.3	113
12	Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. Frontiers in Cellular Neuroscience, 2015, 9, 40.	1.8	110
13	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
14	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Frontiers in Cellular Neuroscience, 2014, 8, 75.	1.8	100
15	Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-Î ² mRNA Levels Accurately Predict Treatment Response in Depressed Patients. International Journal of Neuropsychopharmacology, 2016, 19, pyw045.	1.0	100
16	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and <scp>A</scp> lzheimer disease. Annals of Neurology, 2014, 76, 813-825.	2.8	91
17	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. International Journal of Neuropsychopharmacology, 2010, 13, 103.	1.0	82
18	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry, 2002, 51, 480-484.	0.7	81

#	Article	IF	CITATIONS
19	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.4	80
20	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters, 2008, 437, 130-134.	1.0	79
21	Serum levels of brain-derived neurotrophic factor in drug-naÃ⁻ve obsessive–compulsive patients: A case–control study. Journal of Affective Disorders, 2010, 122, 174-178.	2.0	76
22	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	1.5	76
23	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1322-1325.	2.5	73
24	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. PLoS ONE, 2015, 10, e0116686.	1.1	65
25	VEGF serum levels in depressed patients during SSRI antidepressant treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 146-149.	2.5	61
26	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 323-329.	1.8	54
27	Association between IL-11² -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. Journal of Psychiatric Research, 2003, 37, 457-462.	1.5	52
28	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.4	51
29	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of Neurology, 2013, 260, 640-650.	1.8	50
30	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004, 356, 119-122.	1.0	49
31	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	0.7	47
32	-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study. Brain, Behavior, and Immunity, 2007, 21, 450-457.	2.0	44
33	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	1.8	44
34	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. Psychiatry Research, 2001, 104, 1-9.	1.7	40
35	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit–hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2014, 23, 173-177.	2.8	40
36	Abnormal Levels of cAMP-dependent Protein Kinase Regulatory Subunits in Platelets from Schizophrenic Patients. Neuropsychopharmacology, 2000, 23, 216-219.	2.8	36

#	Article	IF	CITATIONS
37	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2011, 35, no-no.	1.4	36
38	Distinct cerebrospinal fluid amyloidâ€beta peptide signatures in cognitive decline associated with <scp>A</scp> lzheimer's disease and schizophrenia. Electrophoresis, 2012, 33, 3738-3744.	1.3	34
39	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	2.2	34
40	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. BioTechniques, 2014, 57, 111-114.	0.8	34
41	Glucose metabolism alterations in patients with bipolar disorder. Journal of Affective Disorders, 2015, 184, 293-298.	2.0	34
42	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. European Journal of Human Genetics, 2006, 14, 443-449.	1.4	33
43	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Alzheimer's and Dementia, 2012, 8, 520-527.	0.4	32
44	Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain, Behavior, and Immunity, 2018, 70, 315-324.	2.0	31
45	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
46	Association Study of –1727 A/T, –50 C/T and (CAA) _n Repeat GSK-3β Gene Polymorphisms with Schizophrenia. Neuropsychobiology, 2004, 50, 16-20.	0.9	29
47	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. Neuropsychobiology, 2002, 46, 17-21.	0.9	27
48	Effects of Intranasal Oxytocin on Longâ€īerm Memory in Healthy Humans: A Systematic Review. Drug Development Research, 2016, 77, 479-488.	1.4	25
49	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. Journal of ECT, 2019, 35, 189-194.	0.3	19
50	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. Frontiers in Aging Neuroscience, 2020, 11, 366.	1.7	17
51	Oxidation of propenoidic phenols catalysed by N,N′-ethylenebis(salicylideneiminato)cobalt(II) [Cosalen]: reactivity and spectroscopic studies. Journal of Molecular Catalysis A, 1996, 112, 347-351.	4.8	16
52	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. BMC Neuroscience, 2010, 11, 16.	0.8	16
53	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. HA¶gre Utbildning, 2021, 12, 1987655.	1.4	16
54	Childhood trauma and glucose metabolism in patients with first-episode psychosis. Psychoneuroendocrinology, 2020, 113, 104536.	1.3	15

#	Article	IF	CITATIONS
55	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in firstâ€episode psychosis. Microbial Biotechnology, 2020, 14, 507-511.	0.9	15
56	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. Drug Development Research, 2020, 81, 593-599.	1.4	14
57	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 712-715.	0.9	12
58	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. World Journal of Biological Psychiatry, 2018, 19, 610-618.	1.3	12
59	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. Molecular and Cellular Neurosciences, 2017, 85, 220-225.	1.0	11
60	Oxidation of isosafrole by sodium hypochlorite catalysed by manganese porphyrins: Unusual competition between epoxidation and O-dealkylation. Tetrahedron Letters, 1996, 37, 1091-1094.	0.7	9
61	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. Aging Clinical and Experimental Research, 2005, 17, 445-448.	1.4	9
62	Season of birth and inflammatory response system in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 879-880.	2.5	8
63	Effect of the Xbal polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	1.0	8
64	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. Neuropsychobiology, 2016, 74, 15-21.	0.9	8
65	Nanomedicine in Psychiatry: New Therapeutic Opportunities from Research on Small RNAs. Drug Development Research, 2016, 77, 453-457.	1.4	4
66	No occurrence of the glutamate transporter EAAT2 A206G polymorphism in schizophrenic subjects. Molecular Psychiatry, 2002, 7, 671-672.	4.1	3
67	Effetti biomolecolari del maltrattamento infantile: il ruolo dell'epigenetica e dell'infiammazione. Maltrattamento E Abuso All'Infanzia, 2015, , 35-54.	0.2	3
68	Aspetti biologici e neuropsicologici del maltrattamento e abuso infantili. Maltrattamento E Abuso All'Infanzia, 2015, , 7-10.	0.2	2